Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders

A technology for diseases and diseases, which is applied in the field of combination therapy for the treatment of amyotrophic lateral sclerosis and related diseases, and can solve the problems of no microglia and no efficacy

Pending Publication Date: 2021-06-04
THE GENERAL HOSPITAL CORP
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Multiple anti-inflammatory drugs have been tested with little or n

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
  • Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
  • Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0163] method

[0164] chemical reagent

[0165] Sodium cromolyn was supplied by AZTherapies, dissolved in PBS. A 100 mM solution was used for in vivo experiments. Dulbecco's PBS was used to dilute the solution for intraperitoneal injection as previously described, with a final dose of 6.3 mg / kg.

[0166] animal

[0167] 149 mice were used in this study. All animal care, husbandry, and experiments were performed in accordance with guidelines established by the Massachusetts General Hospital Subcommittee on Research Animal Care. These experiments were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee (2014N000018). All mice had free access to food and water. Mice were regularly assessed for dyskinesia and euthanized at the onset of severe paralysis (neurological score = 4, see Neurological Score below) to minimize distress, as previously described. Mice exhibiting mild paralysis (neurological score = 2) were fitted with water bo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Described herein are methods of treating neuron inflammation conditions, for example, amyotropic lateral sclerosis and prion disease, comprising administering a therapeutically effective amount of a combination of cromolyn or a cromolyn derivative compound and an anti-inflammatory agent.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Application No. 62 / 654,772, filed April 9, 2018, the entire contents of which are incorporated herein by reference. Background technique [0003] Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a specific disease that causes the death of neurons that control voluntary muscles. ALS is characterized by muscle stiffness, muscle twitching, and progressively worsening weakness due to a decrease in muscle size. This can cause difficulty speaking, swallowing, breathing and eventually death. [0004] ALS is estimated to affect as many as 30,000 people in the United States, with 5,000 new cases diagnosed each year. Most people with ALS are between the ages of 40 and 70, although the disease can occur at a younger age. Global ALS prevalence was independent of race, ethnicity, or socioeconomic group. ALS is responsible for an estimated 5 out of 10...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/335A61K31/35A61K31/352C07D311/02C07D311/04C07D311/22
CPCA61K31/352A61K31/353A61K45/06A61P25/00A61P25/16A61P25/28A61K31/366A61K31/428A61K31/24A61K31/137A61K31/603A61K31/5415A61K31/192A61K31/4745A61K38/1774A61K2300/00A61K31/122A61K31/045A61K31/616A61K9/0019A61P21/00C07D311/02C07D311/04C07D311/22C07D407/12
Inventor D·R·埃尔马列
Owner THE GENERAL HOSPITAL CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products